AstraZeneca PLC is 147.6x more valuable than Avidity Biosciences, Inc. by market capitalization ($286.27 B vs $1.94 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RNA | AZN |
|---|---|---|
| Market cap | $1.94 B | $286.27 B |
| US-listed rank | #2127 | #47 |
| Revenue (latest FY) | $18.75M | - |
| Net income (latest FY) | -$684.63M | - |
| Net margin | -3650.4% | - |
| SEC filings | 547 | 1,004 |
AstraZeneca PLC is 147.6x more valuable than Avidity Biosciences, Inc. by market capitalization ($286.27 B vs $1.94 B).
Full pages: Avidity Biosciences, Inc. and AstraZeneca PLC, or browse the full rankings.